AC Immune Earnings Call Transcripts
Fiscal Year 2025
-
Interim phase 2 results for ACI-7104 in early Parkinson's disease show strong safety, robust antibody response, and stabilization of key biomarkers and motor symptoms, suggesting potential disease modification. Plans are underway to accelerate development and expand future trials.
-
The conference highlighted a robust pipeline in neurodegenerative disease, emphasizing precision medicine, active immunotherapy, and small molecule innovation. Key data readouts and clinical milestones are expected by year-end, supporting both partnered and wholly owned programs.
Fiscal Year 2024
-
A diverse pipeline is advancing with strong partnerships, robust financials, and recent clinical progress in Parkinson's and Alzheimer's programs. Key milestones are expected in 2024–2025, with a strategic focus on prevention and precision medicine.
-
A broad CNS pipeline is advancing with major partnerships, including a $2.1B deal for ACI-24.060 with Takeda and a phase IIb Tau vaccine with Johnson & Johnson. Active immunotherapies show strong safety and long-term potential, with key data readouts and internal priorities focused on Parkinson’s and inflammation assets.